Price
$6.19
Increased by +0.16%
Dollar Volume
1.89 M
ADR%
4.89
Earnings Report Date (estimate)
Mar 15, 23 (-0.34)
Market Cap.
362.49 M
Shares Float
35.90 M
Shares Outstanding
58.56 M
Beta
1.14
Price / Earnings
-5.60
BPR
350.28
20D Range
5.75 7.10
50D Range
5.11 7.18
200D Range
2.35 7.99
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -0.25
Increased by +7.41%
-0.34
Increased by +26.47%
Aug 5, 22 -0.30
Decreased by -7.14%
-0.31
Increased by +3.23%
May 5, 22 -0.29
Decreased by -16.00%
-0.31
Increased by +6.45%
Mar 17, 22 -0.27
Increased by +10.00%
-0.28
Increased by +3.57%
Oct 28, 21 -0.27
Decreased by -17.39%
-0.26
Decreased by -3.85%
Aug 5, 21 -0.28
Decreased by -12.00%
-0.24
Decreased by -16.67%
May 6, 21 -0.25
Increased by +26.47%
-0.27
Increased by +7.41%
Mar 11, 21 -0.30
Increased by +36.17%
-0.28
Decreased by -7.14%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-14.55 M
Increased by +7.86%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-17.78 M
Decreased by -19.04%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-16.79 M
Decreased by -48.70%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-15.75 M
Decreased by -39.52%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-15.79 M
Decreased by -78.01%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-14.94 M
Decreased by -98.62%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-11.29 M
Decreased by -14.41%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-11.29 M
Increased by +14.20%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.